GE scores first Senographe installation
GE Medical Systems has made its first commercial installation of Senographe 2000D, the company’s full-field digital mammography system. The unit received the CE Mark for European regulatory clearance this spring (SCAN 3/17/99), and on Sept. 2
GE Medical Systems has made its first commercial installation of Senographe 2000D, the companys full-field digital mammography system. The unit received the CE Mark for European regulatory clearance this spring (SCAN 3/17/99), and on Sept. 2 Senographe was placed at Charite Hospital in Berlin. The Milwaukee-based firm plans to install more than 50 Senographes outside the U.S. by the end of the year.
Senographe 2000Ds digital detector is based on amorphous silicon flat-panel detectors manufactured in the companys plant in Santa Clara, CA, a joint venture between GE and EG&G Amorphous Silicon (SCAN 9/3/97) The detectors are then shipped to France, where they are incorporated into Senographe systems built at the companys x-ray and mammography factory in Buc.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
